-- 芬兰国有能源公司富腾（Fortum）周三公布的第一季度财报显示，其发电量、需求和价格均大幅增长。 该公司总发电量从去年同期的12.3太瓦时（TWh）增至13.0太瓦时，主要得益于水力发电量从5.2太瓦时增至5.9太瓦时。 其他业务板块表现不一，核电发电量从6.5太瓦时降至6.4太瓦时，风电发电量维持在0.3太瓦时不变，而热电联产发电量则从0.3太瓦时略微增至0.4太瓦时。 需求方面，北欧电力销售量小幅增长至15.2太瓦时（TWh），高于去年同期的15.0太瓦时，其中包括12.2太瓦时的北欧直接销售量。同时，北欧地区的热力销售量达到1.0太瓦时，其他市场达到1.6太瓦时，分别高于去年同期的0.8太瓦时和1.5太瓦时。 该公司还实现了较高的实际价格，达到每兆瓦时62.5欧元（73.14美元），高于去年同期的60.1欧元。该公司表示，这主要得益于“强劲的两位数优化溢价”，即通过交易和资产优化活动在现货价格之上获得的额外收益。 富腾预计其2026年的核电发电量将在23.5至24太瓦时之间，略低于此前的预期。 该公司还以每兆瓦时 39 欧元的平均价格对 2026 年剩余时间的 75% 发电量进行了套期保值，并以每兆瓦时 40 欧元的价格对 2027 年预期产量的 60% 进行了套期保值。
Related Articles
Asia
ICBC Sells 50 Billion Yuan Bonds
Industrial and Commercial Bank of China (HKG:1398, SHA:601398) or ICBC completed the issue of 50 billion yuan of four-year bonds carrying an interest rate of 1.79%, according to a Wednesday Hong Kong bourse filing.The lender has a conditional redemption right at the end of the third year.The firm intends to use proceeds to improve its total loss-absorbing capacity.
$HKG:1398$SHA:601398
Asia
DFZQ's Profit Climbs 11% in Q1
Orient Securities (HKG:3958) or DFZQ recorded an 11% rise in attributable profit in the first quarter of 2026 to 1.59 billion yuan from 1.44 billion yuan after adjustment a year prior, according to a Wednesday Hong Kong bourse filing.The securities company's basic EPS rose to 0.19 yuan from 0.16 yuan in the corresponding period of the previous fiscal year.Operating income jumped 5.3% to 4.09 billion yuan from 3.88 billion yuan in the year-ago period.
$HKG:3958
Research
Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.
$IONS